FindTrial
Sign In

Extension study following the phase I/II clinical study of CT-P13 in the patients with rheumatoid arthritis

Extension study following the phase I/II clinical study of CT-P13 in the patients with rheumatoid arthritis

Status
Unknown
Phases
Phase 2
Study type
Interventional
Source
JPRN
Registry ID
JPRN-jRCT2080222369
Enrollment
Unknown
Registered
2014-01-16
Start date
2014-01-16
Completion date
Unknown
Last updated
2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Rheumatoid arthritis

Interventions

investigational material(s) Generic name etc : CT-P13 INN of investigational material : Therapeutic category code : 399 Agents affecting metabolism, n.e.c. Dosage and Administration for Investigation

Sponsors

Nippon Kayaku Co., Ltd.
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: (1) Patients who have completed final observation after 54-week administration in the phase I/II clinical study and whose symptoms are stable. (2) Patients for whom administration of CT-P13 is deemed appropriate as of the end of final observation after 54-week administration in the phase I/II clinical study.

Exclusion criteria

Exclusion criteria:

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026